Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...114115116117118119120121122123124...136137»
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, efgartigimod IV (ARGX-113 IV) / argenx, Broteio, Rituxan (rituximab) / Roche, Biogen
    Review, Journal:  Immunotherapy in myasthenia gravis in the era of biologics. (Pubmed Central) -  Jan 30, 2020   
    Belimumab, an antibody against the B cell trophic factor BAFF, was ineffective in phase III trials, and efgartigimod, which depletes antibodies, was effective in a phase II study...Checkpoint inhibitors can trigger MG in some patients, necessitating early intervention. Increased availability of new biologics provides targeted immunotherapies and the opportunities to develop more specific therapies.
  • ||||||||||  Trial completion date, Trial primary completion date:  Neurology Inpatient Clinical Education Trial (clinicaltrials.gov) -  Jan 27, 2020   
    P=N/A,  N=80, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
  • ||||||||||  fentanyl citrate / Generic mfg., prednisone / Generic mfg., Ultane (sevoflurane) / Generic mfg.
    Clinical, Journal:  Mitral Valve Replacement with Thymectomy in a Patient with Ocular Myasthenia Gravis: Case Report. (Pubmed Central) -  Jan 26, 2020   
    The postoperative course was uneventful, the patient was extubated at 6 hours postoperatively, in-tensive care unit stay was 48 hours, and the patient was discharged after 6 days without any compli-cations. After 3 months, at the follow-up examination, the patient's ocular symptoms (eyelid ptosis) disappeared.
  • ||||||||||  Journal, IO Biomarker:  Association between CTLA-4 gene polymorphism and myasthenia gravis in a Chinese cohort. (Pubmed Central) -  Jan 24, 2020   
    A haplotype containing rs733618*C, rs231775*G and rs3087243*G is identified to increase the general risk of MG by 1.278-fold and ocular onset MG subgroup by 1.362-fold. There is association of rs733618 with the general susceptibility of MG, and association of rs231775 and rs3087243 with the susceptibility of ocular onset MG, but no association with the severity of MG.
  • ||||||||||  Myasthenia Gravis () -  Jan 22, 2020 - Abstract #AAN2020AAN_4813;    
  • ||||||||||  C57 - Neuromuscular Junction Disorders 1: Myasthenia Gravis, Ocular, and MuSK Myasthenia () -  Jan 22, 2020 - Abstract #AAN2020AAN_3678;    
    Case presentations will demonstrate a practical approach to identification, evaluation, and management of common and more challenging patients in the clinical setting with additional information about recently approved products and potentials treatments in future. This program complements Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome, and Less Common Disorders of Neuromuscular Transmission, but covers independent topics.
  • ||||||||||  Myasthenia Gravis in Monozygotic Twins () -  Jan 21, 2020 - Abstract #AAN2020AAN_2848;    
    Similarly, this case prompts to question the direct role of the antibody in clinical manifestation and disease severity. Additionally, we are brought to wonder the prevalence of seropositive individuals who are asymptomatic and never manifest any clinical symptoms, as this case would suggest a new population of individuals to study further for improved pathological understanding.
  • ||||||||||  Risk of generalization in ocular myasthenia gravis after 10 years. () -  Jan 21, 2020 - Abstract #AAN2020AAN_2847;    
    The proportion of generalization in our study was in accordance with recent cohort. Prospective observational cohort with a large number of patients seems necessary to overload statistical limitation and identify prognosis factor
  • ||||||||||  Inflammatory Myopathy with Superimposed Myasthenia Gravis – A Rare Overlap Syndrome () -  Jan 21, 2020 - Abstract #AAN2020AAN_2529;    
    We report a rare case of overlap myositis evidenced by coexistence of dermatomysotis sine dermatitis and myasthenia gravis. When treating a myopathy and clinical deterioration is appreciated with high dose steroids, it is prudent to consider this rare overlap syndrome.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Ocular Myasthenia Gravis – How Effective is Low Dose Prednisone Long Term? () -  Jan 21, 2020 - Abstract #AAN2020AAN_2498;    
    Conversion to GMG remains low on low dose prednisone and / or other immunosuppressive agents. Prednisone remains the main therapy for OMG but it is not a cure or ultimate panacea.
  • ||||||||||  When My-“asthenia” is NOT due to Myasthenia Gravis () -  Jan 21, 2020 - Abstract #AAN2020AAN_2433;    
    If the diagnosis is not made accurately, patients may be exposed to procedures and treatments they may not need, which may even cause potential harm. Certain characteristics of myasthenia gravis, or its treatment, may, in fact, predispose patients to developing these conditions.
  • ||||||||||  Autoimmune Myocarditis Associated to Seropositive Myasthenia Gravis () -  Jan 21, 2020 - Abstract #AAN2020AAN_2430;    
    Heart muscle involvement of myasthenia gravis and its underlying pathophysiology needs to be carefully evaluated in these patients to establish the appropriate management plan. These include autoimmune myocarditis, giant cell myocarditis, stress-induced cardiomyopathy (i.e. takotsubo), pericarditis post-irradiation for thymoma, arrhythmias, medication-induced cardiac disease, among others.
  • ||||||||||  Retrospective Analysis of Comorbidities Associated with Myasthenia Gravis () -  Jan 21, 2020 - Abstract #AAN2020AAN_2428;    
    Individualized plan for post-discharge continuation of IVIg/PLEX with no other changes may also decrease the readmission rate. In conclusion, many patients diagnosed with MG experience comorbid events within the first 12 months, most frequently including steroid and immunosuppressive related complications followed closely by infections and other neurological conditions.
  • ||||||||||  Validation of the Spanish Version of the 15-Item Myasthenia Gravis Quality of Life Scale (MG-QOL15) () -  Jan 21, 2020 - Abstract #AAN2020AAN_2427;    
    At Harbor UCLA Medical Center, we have recently translated the MG-QOL15 into Spanish and demonstrated that even with a small sample size, the data suggests that the MG-QOL15S is valid and reliable. We aim to expand our recruitment efforts to 2 additional neuromuscular clinics as well as compare to another established QOL scale, the 36-item Short Form(SF-36).
  • ||||||||||  Positive Acetylcholine Receptor Antibody - A Subtle Sign of An Occult Endometrial Cancer () -  Jan 21, 2020 - Abstract #AAN2020AAN_2425;    
    Our MuSK-MG patients’ demographics, symptomatology, and treatment responsiveness were in concordance with phenotypes described in existing literature. We report the first ever case of endometrial adenocarcinoma prospectively diagnosed after a positive α3-AchR Ab tested to establish the etiology of peripheral neuropathy and muscle weakness.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Survey to assess variability in management of myasthenic crisis among neurologists () -  Jan 21, 2020 - Abstract #AAN2020AAN_2424;    
    Our survey indicates that there is considerable variability in the acute treatment of myasthenic crisis, and escalated therapy continues into the post-discharge recovery period. We intend to collate data from a much larger community of clinicians and have this available for presentation at the annual meeting.
  • ||||||||||  Interactions Between Myasthenia Gravis and Pregnancy () -  Jan 21, 2020 - Abstract #AAN2020AAN_2423;    
    The risk of Caesarean delivery was similar to the general population. A high proportion of patients worsened during pregnancy, especially in patients with MG for less than 2 years.
  • ||||||||||  B cell subsets and T follicular helper cells in myasthenia gravis thymus () -  Jan 21, 2020 - Abstract #AAN2020AAN_2374;    
    We found the increase of plasma blast and unchanged Tfh cells in MG thymuses. We postulate that increased plasma blast contributes to produce the antibodies in MG thymus, but immunosupresive therapy before thymectomy might inhibit lymphoproliferative response leading to the ectopic germinal centers.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Effect of Complement Inhibition on Lymphocytes in Treatment Refractory Myasthenia Gravis Patients () -  Jan 21, 2020 - Abstract #AAN2020AAN_2373;    
    Immunologically, eculizumab increased the frequency of selected CD8 T cells subsets and unbiased cluster analysis revealed that this increase stems from a rise in naïve and terminal effector CD8 T cells. Ongoing analyses will focus on less common immune subsets and qualitative immune signature changes in patients with a reduced clinical response to complement inhibition.